RxDoctor Payments Data

Denise Garrett, APRN

Nurse Practitioner · Murfreesboro, TNNPI 1801398714

Payments from drug & device makers

$5,835in general payments, 2019–2025

Across 94 payments — averaging $62.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Johnson & Johnson$977
  • Neurocrine Biosciences, Inc.$860
  • Otsuka America Pharmaceutical, Inc.$849
  • AbbVie$636
  • Vanda Pharmaceuticals Inc.$481
  • plus $1K from 6 others

What the payments were for

  • Food & beverage$5,75499%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,835 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$10,435
Medicare patients
43
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$212,609
IngrezzaValbenazine Tosylate23$182,353
CaplytaLumateperone Tosylate65$110,623
VraylarCariprazine Hcl64$97,614
Invega SustennaPaliperidone Palmitate22$58,013
Abilify MaintenaAripiprazole15$41,196
FanaptIloperidone18$40,616
LybalviOlanzapine/Samidorphan Malate11$17,623
Aripiprazole99$13,861
Olanzapine165$7,248
Lurasidone Hcl15$6,746
Paliperidone ErPaliperidone16$5,679
Divalproex Sodium105$4,928
Oxcarbazepine83$4,786
Quetiapine Fumarate ErQuetiapine Fumarate46$4,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$860$182,35323 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,015$110,62365 claims
AbbVieVraylar$636$97,61464 claims
Johnson & JohnsonInvega Sustenna$977$58,01322 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$849$41,19615 claims
Vanda Pharmaceuticals Inc.Fanapt$481$40,61618 claims
Alkermes, Inc.Lybalvi$227$17,62311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →